Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

MISSISSAUGA, ON, May 26, 2025 /CNW/ - GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance ...

Mississauga, Ontario Tuesday, May 27, 2025, 16:00 Hrs [IST] ...

SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo ANCHOR-1 and -2 trials ...

I was prescribed the drugs tambulosin and finasteride for an enlarged prostate. But I was never warned that they might make ...